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Objectives: In publicly funded health systems such as the United Kingdom (UK) 
National Health Service (NHS), patients do not normally face the full economic 
cost of treatment decisions, nor are they aware of the potential cost to the sys-
tem. We investigated whether patient awareness of treatment costs, either to the 
system or to themselves, would affect treatment choices. MethOds: 344 repre-
sentative members of the UK public were recruited via an online survey panel. 
Respondents were required to make treatment decisions in three different health 
conditions (sore throat, psoriasis and sciatica). Respondents were presented with 
condition-specific patient decision aids (Option Grids™), each supported by: 1) no 
cost information, 2) cost to the NHS (drug/ procedure tariff), 3) cost to patient (drug/ 
procedure tariff), and 4) access cost to patient (flat cost for all options). Differences 
in treatment choices were explored using ANOVA. Significant differences within 
each health condition were subsequently explored using t-tests. Results: A sig-
nificant number of respondents switched choice to the cheapest intervention when 
tariff costs to either the system (p< 0.05) or themselves (p< 0.01) were considered 
versus no cost information when choosing between treatments for psoriasis. For 
all three health conditions, presenting flat access costs increased the likelihood 
(p< 0.01) of respondents choosing the treatment option known to have the highest 
tariff price. cOnclusiOns: Cost information influences treatment decisions. We 
observed that awareness of cost to the system or to oneself encouraged the choice 
of lower priced treatment options, whereas flat access charges encouraged the 
choice of treatment known to be more expensive. Provision of cost information may 
therefore be important for informed decision making, and could also be a policy 
tool to generate cost savings for the health system.
PIH71
HealtH lIteracy and Self-rePorted HealtH StatuS uSIng tHe eq-
5d-5l: an exPloratory analySIS
Rey-Ares L.1, Augustovski F.2, Irazola V.3, Garay O.U.4, Gianneo O.5, Fernández G.5, Morales M.5
1Institute for Clinical Effectiveness and Health Policy (IECS), CABA, Argentina, 2Economic 
Evaluations & HTA Department; Institute for Clinical Effectiveness and Health Policy (IECS) 
and Professor of Public Health, University of Buenos Aires, Buenos Aires, Argentina, 3Institute 
for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina, 4IECS Institute for 
Clinical Effectiveness and Health Policy, Buenos Aires, Argentina, 5Fondo Nacional de Recursos, 
Montevideo, Uruguay
Objectives: To describe health literacy (HL) in Uruguayan general population 
and its relation with self-reported health status. MethOds: As part of an ongoing 
Uruguayan EQ-5D-5L valuation study, we included the Short Assessment of Health 
Literacy-Spanish questionnaire (SAHL-S), a previously validated instrument that 
evaluates HL through 18 items combining word recognition and comprehension. 
Low HL is defined by identifying ≤ 14 correct items. We included participants with 
valid SALH-S responses, complete sociodemographic characteristics, self-reported 
health status with the EQ-5D-5L, and report of previous experience with illness. 
This preliminary analysis describes sociodemographic characteristics, HL and self-
reported health status and explores the independent association between EQ visual 
analogue scale (VAS) score and HL using standard linear regression. Results: Of 
773 participants 60.2% were women (mean age 42.02 years; SD: 15.51). VAS mean was 
79.34 (DS: 16.39). 52.9% participants had at least one limitation in any of the EQ-5D 
domains, 75.9% had experience with illness and 51% in caring others. Educational 
attainment (EA) distribution was 17.2% up to primary, 52.3% up to secondary and 
30.5% up to tertiary or higher education. Low HL was present in 39.8% of the popu-
lation. In bivariate analysis aging and low HL were associated with poorer VAS 
scores (coef -0.276; p= 0.000; coef -3.028; p= 0.012). Higher VAS scores were observed 
with higher EA (coef 2.832; p= 0.001). Multiple regression shows HL is related to VAS 
independently of age, but this association loses its statistical significance -becom-
ing borderline- after adjusting for EA and experience in caring others (coef -1.93; 
p= 0.098). cOnclusiOns: HL is a recently developed construct that combines for-
mal education and acquired knowledge related to health. This is the first study that 
describes HL in Uruguay, and shows that is associated with self-reported health. 
Further studies are needed to explore the potential value added to standard edu-
cational level measurement.
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Objectives: The objective of this study was to assess the translatability of “frus-
trated,” a term commonly used to describe a range of emotions in Clinical Outcomes 
Assessments (COA). “Frustrated” includes many constructs, such as “discourage-
ment,” “anger” and “upset.” Previous studies have shown that terms including mul-
tiple constructs in English, such as “bother,” are not sufficiently translatable across 
all languages. MethOds: Back-translations of questionnaires containing the word 
“frustrated” were analyzed to assess the translatability of the term. The following 
related constructs were also included in analysis: “discouraged,” “angered,” “disap-
pointed” and “upset.” Data collection forms resulting from cognitive debriefing were 
also analyzed to determine subjects’ interpretation of “frustrated” as translated in 
other languages. Results: “Frustrated” proved to be very problematic for 13 out 
of the 24 languages in this study, most notably for Eastern European, Indian and 
Asian languages. For example, “frustrated” was translated as “indignant” in Greek, 
“disillusioned” in Hungarian, “irritated” in Japanese and “discouraged” in Korean. 
Out of 245 subjects, 13% took issue with “frustrated,” indicating that it was not 
understood or not appropriate for their languages. Analyses of related constructs 
showed that “discouraged” and “angered” were best suited for use, as these terms 
were translated with no issues in all 12 languages available for analysis. “Upset” 
was found to be equally problematic, and thus rejected as a recommended con-
struct. cOnclusiOns: “Frustrated” is not recommended for use in COAs intended 
for international data pooling. Similar to the findings of previous studies, more spe-
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Objectives: Setting priorities with limited public resources has gained heated 
interests worldwide. Weighting health gains differently for different groups in the 
population is another manner to consider equity in cost-effectiveness analysis. 
However, there is only a few empirical analysis eliciting general public preference. 
This research is to compare equity weights of Japanese and Korean. MethOds: We 
conducted a web-based survey in Mar 2013 including a discrete choice experiment 
(DCE) to elicit general publics’ equity weight for life gains of those from different 
groups. We selected attributes and designed this experiment following manners 
used in Norman (2013). Thus, we analyzed weights according to the difference of 
gender, smoking status, life style, caring status, income and age. Results: 1,280 
Japanese and 580 Koreans completed questionnaires and were eligible for analysis. 
Japanese put higher weight on male (p< 0.001), non-smokers (p< 0.001), those with 
lower income (p< 0.001), carer (p< 0.001) and those with an expected age of death 
less than 45 years (p< 0.001). Korean have the same patterns of preference accord-
ing to income (p< 0.001), caring (p< 0.001) and smoking status (p= 0.026). However, 
they equally consider groups from different gender (p= 0.331) and age groups. For 
both countries, respondents tend to prefer groups with same characteristics as 
them. cOnclusiOns: People from two Asian developed countries with universal 
health insurance shows different equity weights. These may reflect the variations 
of cultural backgrounds and coverage of health care services.
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Objectives: The growth of pharmaceutical expenditure and patients’ out of pocket 
has motivated researchers to explore underlying factors affecting on generic sub-
stitution both in developed and developing countries. The purpose of this study is 
therefore to explore how Iranian people think about generic medicines and what 
underlying factors should be taken into account by policy makers to promote the 
culture of generic substitution. MethOds: A cross-sectional descriptive study invit-
ing Iranian people was performed using a self-administrated anonymous question-
naire. Besides the demographic section, 34 items of developed questionnaire were 
categorized to 7 main factors including: experience of patients, efficiency of medi-
cines, cost of medicines, physician’s role, pharmacist’s role, negetive perception of 
patients and government interventions. Results: After analyzing 1310 completed 
questionnaires, results showed the among the aforementioned factors the govern-
ment interventions has the first priority to encourage patients to use of generics 
medicines instead of brand medicines and followed by physician’s role, pharmacist’s 
role, efficiency of medicines, cost of medicines, experience of patients and negetive 
perception of patients. cOnclusiOns: In conclusion, the trust of Iranian’s society 
to the government, physicians and pharmacists would be a worthy opportunity to 
reduce health care expenditure as well as patients’ out of pocket by taking evidence- 
based decisions toward promotion of generic substitution.
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Objectives: This study assessed the quality of life associated with various states 
of erectile dysfunction (ED) among adults: both diagnosed ED sufferers and non-
sufferers in Germany, the United Kingdom and the United States. MethOds: A 
multi-national, cross-sectional online survey was conducted among a representa-
tive sample of 2,000 adults (n= 500 Germany, n= 500 UK, n= 1,000 US) with an equal 
number of men and women in a heterosexual relationship. Respondents rated 
either their or their partner’s erectile function, and health state utilities were 
measured using standard gamble (SG) and visual analog scale (VAS) in counter-
balanced order. Utilities were estimated for one level from the Erection Hardness 
Scale: penis gets hard but not hard enough for penetration. Differences were exam-
ined by measure, country and respondent demographics. Results: The SG and 
VAS measures yield similar, but not identical mean estimates for the ED health 
state. Significant variation exists by measure as well as by country. In comparing 
the utility assessments between the countries using SG, German respondents 
have significantly higher average utility (0.49) for ED than do respondents from 
the UK (0.40), and US (0.41). When examining differences by gender, females have 
greater utility for the ED health state when compared to males. Men with ED 
report a lower utility for the ED health state when compared to men without ED. 
By contrast, females whose partners have ED report a higher utility for the ED 
health state when compared to females with partners without ED. Although util-
ity is consistent across most ages, an increase in utility exists for adults aged 75 
and over. cOnclusiOns: Notable differences in ED utility emerged by country: 
Germans have higher utility for ED when compared to UK and US respondents. 
Significant differences in ED utility between males and females suggests there 
is an important relationship disconnect between men with ED and their female 
partners.
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had “symptoms” as a primary endpoint; a drug for rheumatoid arthritis (RA) had 
“functioning” as its lead secondary endpoint; the remaining six drugs (for pulmo-
nary arterial hypertension (PAH), Crohn’s Disease, smoking cessation, Myasthenia 
Gravis, asthma, and overactive bladder) had “HRQOL”, “symptoms, and “functioning” 
as minor secondary endpoints. Three drugs -indicated for PAH, seizure, and RA- had 
PRO claims in their labels. cOnclusiOns: Although not yet prominent in Japan, 
PROs are used in drug clinical trials and label claims. Symptoms, Quality of Life, and 
Functioning are the most common PROs used.
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Objectives: Interest in delivering Patient Reported Outcome Measures (PROMs) 
using mobile devices (e-PROMs) has increased in recent years. However there is 
debate about the level of equivalence between the traditional pencil and paper 
and electronic modes of administration. The aim of this study is to compare the 
equivalence of delivering a widely used generic PROM (EQ-5D-5L) pencil and paper 
and mobile phone administration modes. MethOds: A mobile version of the 
EQ-5D-5L was developed with guidance from the EuroQol Group. Two hundred 
respondents from a research cohort of people in South Yorkshire were identified, 
and randomly allocated to one of the administration modes based on stratifications 
for age and gender (and across a range of self-reported health issues). The EQ-5D-5L 
was completed either using a mobile device or the standard paper version which 
were sent out to the respondent. Follow up usability questions were also included. 
EQ-5D equivalence was compared at the dimension and utility and VAS score level 
using ANOVA. Results: Response rates were comparable across the arms, with 
the majority of respondents owning a smartphone. The mean EQ-5D-5L utility and 
VAS scores and the frequency of respondents endorsing the individual EQ-5D-5L 
categories across each of the dimensions does not differ across the administration 
modes. The majority of the mobile phone completion sample agreed that the mobile 
version of EQ-5D-5L was easy to complete, and that the phone was easy to use, and 
that they would complete e-PROMs again. cOnclusiOns: Completing e-PROMs 
using mobile phones produces equivalent results and response rates to pencil and 
paper methods, and respondents are positive towards completing questionnaires 
using these methods. This provides evidence that e-PROMs are valid for use to 
collect data in a range of settings including clinical trials, routine care, and as, for 
example, health diaries.
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Objectives: Increasingly, patients become active participants in making decisions 
on their therapy. A survey was conducted to understand the experience and expecta-
tions of patient organizations (POs) with patient reported outcomes (PRO) as they 
are measured today. MethOds: An online survey was conducted in English lan-
guage throughout May 2014 among 40 participants at a global cross disease patient 
forum to prepare a discussion of the relevance and usefulness of patient reported 
outcomes from the patient perspective. The participants represented a broad range 
of disease specific and disease independent patient organizations from various 
countries including USA, European countries, Asia, Latina America, Middle East 
and Australia. Results: Current PROs were perceived as useful but not optimal 
for informing patients in making their own therapy decisions. All of 9 typical PRO 
domains were considered important (between 3.9 and 4.7 on a 5 point scale) with 
the most important being symptoms (4.6±0.89), Physical Function (4.65±0.59) and 
psychological well-being (4.7±0.47). The participants thought that PROs should be 
part of all studies throughout the entire life cycle of products including evidence 
for clinical research, reimbursement decisions, listing decisions, health technology 
assessment (HTA) or comparative effectiveness (CER) studies (all between 4.25 and 
4.6 on a 5-point scale). Increasingly, POs develop their own instruments to elicit 
PROs from the patient perspective and as patient based evidence. cOnclusiOns: 
The concept of patient reported outcomes is good in principle but more is needed 
for integrating additional aspects which are relevant for the patients themselves 
to understand the full impact and consequences of the therapy. Patient reported 
outcomes are a key endpoints from the patient perspective and should be elicited 
throughout the entire development and marketing cycle of products.
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Objectives: To migrate the UK English Endometriosis Health Profile (EHP) from 
paper to ePRO format for completion by respondents on a touchscreen tablet device. 
Following migration, to produce translations of the UK English ePRO version in 
25 languages. MethOds: The draft ePRO version of the EHP was reviewed by the 
questionnaire developer, the translation project manager and the sponsor. During 
the initial review the questionnaire was assessed for linguistic equivalence with 
the paper version and for usability in relation to the target patient group. A number 
of factors were considered including layout, response input method and forced 
completion. Decisions were made based on the recommendations of the developer, 
translation vendor and ePRO vendor according to the specialism of each party, tak-
ing into consideration the capabilities of the software and the requirements of the 
cific terms, such as “discouraged” and “angered,” translate with greater conceptual 
equivalency. Therefore, when seeking to measure the various concepts associated 
with the term “frustrated,” measuring more specific constructs independently using 
separate questionnaire items is recommended.
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Objectives: To demonstrate the increasing use of mobile phones to collect patient 
reported outcomes in research as a valid method of data collection. MethOds: A 
literature search was conducted looking at articles published between 2009 and 2014 
that referenced electronic diaries of some description. Articles were pulled out that 
specifically referenced mobile or cellular phones. Results: 39 of out of 191 articles 
found specifically referenced mobile. The studies referenced were carried out on 
populations with an age range of 8 years up to 80 (mean 35.4; SD 16.6) and were split 
into 15 therapy areas including metabolic and genetic disorders, pain, weight man-
agement, sexual activity, respiratory, multiple sclerosis and gastroesophageal reflux 
disease. Population size ranged from 12 to 994 (mean 208.3; SD 269.2), and subjects 
reported for a minimum of 7 days (up to 6 reports per day) to a maximum of 2 years 
(mean 154.3 days; SD 170.6). Notably, 18 out of the 39 studies allowed the subjects 
to use their own mobile phone for the reporting and 19 articles referenced smart-
phones specifically. cOnclusiOns: All concluded that mobile phones were suited 
to collect data from subjects. It was noted that the use of mobiles was acceptable 
as they are used them in everyday life and found to be convenient; the technology 
was also inexpensive to implement. The fact that 46.2% of the studies allowed the 
subjects to use their own mobile phones for the reporting emphasises the practical-
ity of using mobile phones in patient reported outcomes. Although the mean age of 
all the studies was relatively low, the age range was very wide and researchers can 
be confident that older populations could use mobile phones to collect these data. 
The technical evolution of mobile technologies and ubiquitous nature show that 
this technology is a valid means to collect patient reported outcomes.
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Objectives: According to the Federal, Food, Drug and Cosmetic Act (FD&C Act), 
prescription drug promotion must not be false or misleading, have fair balance, be 
consistent with the approved product labeling, and only include claims substanti-
ated by adequate and well-controlled clinical studies. The Office of Prescription 
Drug Promotion (OPDP), formerly the Division of Drug Marketing, Advertising and 
Communications (DDMAC), was set up to protect the public health by assuring pre-
scription drug information is truthful, balanced and accurately communicated. 
The objective of this study was to review the DDMAC/OPDP warning and notice of 
violations letters to find out 1) how many violations were in relation to PRO and 
HRQL claims and 2) how those evolved after the publication of the FDA PRO draft 
guidance in 2006. MethOds: DDMAC letters were identified on the “Enforcement 
Activities by FDA” webpage. Letters from 1998 to 2013 were all reviewed manually 
to identify violations in relation to PRO and HRQL claims during the periods before 
and after the publication of the guidance (1998-2005 vs. 2006-2013). Results: 763 
letters were reviewed. Each letter included information about one or more viola-
tions of the FD&C Act, such as “Omission of Risk Information”, “Overstatement of 
Efficacy”, “Unsubstantiated Superiority Claims”, etc. The review showed a letter 
volume on the decline (n= 524 for 1998-2005, n= 239 for 2006-2013), with an increase 
in PRO violations: 19.50% of all letters (1998-2005) vs. 30.5% (2006-2013). HRQL vio-
lations were rarer after 2006 and were more often detected as implicit: 20 false 
HRQL claims, of which two were considered implicit (1998-2005) vs. seven false 
HRQL claims, of which four were considered implicit (2006-2013). Examples will be 
presented. cOnclusiOns: The FDA guidance on PRO measure seems to have had 
an influence on HRQL information: less ads with explicit violations and a OPDP’s 
tendency to argue over implicit claims.
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Objectives: The use of patient-reported outcomes (PROs) in label claims in the 
US and Europe is regulated by the US FDA and the EMA, respectively. Japan’s 
Pharmaceuticals and Medical Devices Agency (PMDA) does not have such regu-
lations. This study was done to determine whether Japan-based pharmaceutical 
companies utilize PRO endpoints at all and in what way, by investigating their 
inclusion of PROs in pharmaceutical clinical trials and drug information materi-
als. MethOds: We searched the websites of ClinicalTrials. gov and the PMDA for 
information on 14 drugs which had received PRO claim approvals from both the 
US FDA and EMA from 2006-2010. Search terms were the generic and/or brand 
names of the selected drugs (in English and Japanese, as appropriate). PROs were 
classified as “symptoms”, “functioning”, and “HRQOL” based on the PRO scale used. 
A table comparing PRO type, endpoint positioning, and US and Europe-approved 
label claims versus the PRO information reported in Japan for the same drug was 
created. Results: Of the above fourteen drugs, four are not yet available in Japan. 
One drug with an FDA and EMA-approved “symptoms” claim did not have such in 
its Japan clinical trial. Of the nine remaining drugs, the PRO endpoints were as fol-
lows: two drugs, indicated for epileptic seizure and for benign prostatic hyperplasia, 
